Acromegaly is the small but commercially meaningful endocrine market where the next generation of somatostatin-pathway and growth-hormone-receptor therapeutics is reshaping a category that ran on monthly intramuscular octreotide injections for two decades. Crinetics' Palsonify (paltusotine) — the first once-daily oral SST2 nonpeptide agonist — was approved in the US in late 2025 and won European Commission approval April 27, 2026 across the 27 EU member states plus three EEA countries; Q1 2026 net product revenue was $10.3M with 263 unique prescribers in the first full commercial quarter, and the PATHFNDR-1 and PATHFNDR-2 open-label extensions confirmed durable acromegaly control through two years at ENDO 2026 on June 14.
Camurus's Oclaiz (CAM2029), a once-monthly subcutaneous octreotide FluidCrystal depot, received a second FDA Complete Response Letter on June 10, 2026, tied again to unresolved observations from a September 2024 cGMP inspection at the same third-party manufacturer. Camurus plans to resubmit in Q4 2026 with a second validated manufacturer; the earliest potential US approval is now H1 2027, leaving Palsonify as the only next-generation entrant in the US acromegaly market through at least the first half of next year. EU and UK launches landed in 2025 under the Oczyesa brand. Pfizer's Somavert (pegvisomant) and Ipsen's Somatuline remain in the competitive frame.
The newest entrant came at ENDO 2026 on June 19 when Marea Therapeutics released first-in-human Phase 1 data on MAR002, a first-in-class half-life-extended allosteric monoclonal antibody growth hormone receptor antagonist with pharmacokinetics supporting potential biweekly subcutaneous dosing — a fundamental redesign of the daily-injection pegvisomant approach. Marea plans to advance MAR002 into a Phase 2/3 study in acromegaly in the coming weeks. Stories here cover trial readouts, regulatory milestones, and the broader SST2 and anti-GHR competitive landscape. See [[palsonify]], [[paltusotine]], [[crinetics]], [[camurus]], and [[marea-therapeutics]].
Marea Therapeutics (Endocrine News Pharma Friday, June 19) released Phase 1 first-in-human data for MAR002, a first-in-class half-life-extended allosteric human monoclonal antibody growth hormone receptor antagonist (GHRA), at ENDO 2026 in Chicago. The Phase 1 readout supports a potential best-in-disease profile across safety, tolerability, pharmacodynamic IGF-1 lowering, and pharmacokinetics, with a long duration of action compatible with infrequent subcutaneous dosing — potentially once every two weeks — versus the daily subcutaneous administration required for pegvisomant (Somavert). MAR002 sits at the intersection of acromegaly's existing somatostatin (octreotide, lanreotide, Palsonify), GH-receptor (pegvisomant), and dopamine agonist (cabergoline) approaches and reframes the GHR antagonist class around an antibody, not a pegylated protein. Acromegaly's US/EU prevalence is roughly 40-70 per million.
Crinetics Pharmaceuticals (Nasdaq: CRNX) presented data on June 14 from up to two years of efficacy and pooled safety follow-up in the PATHFNDR-1 and PATHFNDR-2 open-label extensions of Palsonify, the once-daily oral SST2 nonpeptide agonist for acromegaly. Palsonify maintained lowered IGF-1 levels, stable symptoms, and stable or reduced pituitary tumor volumes through 48 weeks across 167 patients. Pooled safety data identified no new safety signals; common adverse events were diarrhea, arthralgia, headache, and UTI. A separate ACROBAT Advance analysis showed safety and efficacy with up to four years of Palsonify + oral cabergoline combination therapy in patients whose IGF-1 had not normalized on Palsonify alone. With Camurus's rival monthly octreotide depot Oclaiz pushed to a 2027 US launch after the June 10 second CRL, Palsonify now stands alone as the next-generation acromegaly therapy in the US market.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will present an oral abstract Sunday June 14 (1:45-3:15 PM CT, Room W183BC) covering up to two years of efficacy and pooled safety data from the Palsonify (once-daily oral paltusotine) PATHFNDR-1 and PATHFNDR-2 open-label extensions in acromegaly, plus long-term combination data with cabergoline from the ACROBAT Advance trial. The presentation lands four days after Camurus's second Complete Response Letter on Oclaiz (CAM2029), the rival monthly subcutaneous octreotide depot, leaves the US acromegaly market with only one approved next-generation entrant (Palsonify, approved September 2025) through at least H1 2027. Crinetics will also present six total abstracts at ENDO including Phase 2 atumelnant data in congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
The Endocrine Society's annual meeting ENDO 2026 opened today at McCormick Place West in Chicago and runs through Tuesday June 16, drawing roughly 7,200 attendees and nearly 2,500 abstracts spanning diabetes, obesity, reproductive health, bone health, endocrine-disrupting chemicals, and thyroid cancer. Saturday's plenary 'Unraveling Hormonal Complexity: Genomics, Sex Differences, and Physiology' features I. Sadaf Farooqi (Cambridge) on single-cell genomics and Holly A. Ingraham (UCSF) on hormones and brain-body physiology. Peptide-anchored programs concentrated in the hypoparathyroidism (Ascendis, MBX, Entera), acromegaly (Crinetics), and oral GLP-1 (Entera EB618 preclinical) tracks; oncology-peptide tracks include OAR-targeted radioligand abstracts and copper-peptide bone-resorption work.
Camurus said on June 10 that the FDA had issued a Complete Response Letter on the Oclaiz (CAM2029) NDA, the second the program has received and the second based solely on unresolved observations from a September 2024 cGMP inspection at a third-party contract manufacturer. The CRL did not cite clinical efficacy or safety. Camurus expects to resubmit in Q4 2026 with a second validated manufacturer; an approval pushed to the first half of 2027 leaves the US launch about a year behind the EU and UK rollouts (under the Oczyesa brand) that landed in 2025.
Camurus's PDUFA target action date for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on FluidCrystal technology, was June 10, and as of June 11 neither the FDA nor Camurus has announced an approval. The acromegaly decision sits in the unannounced-pending bucket that sometimes precedes a same-week communication. Camurus has previously said its US commercial team is launch-ready, with about 20 sales reps active and a Q3 2026 launch targeted if approved; EU and UK marketing authorizations landed in 2025.
Camurus's resubmitted NDA for Oclaiz (CAM2029), a monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target action date of June 10. The resubmission, accepted in January 2026 after a Complete Response Letter tied solely to a third-party manufacturing inspection, rests on data from seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would put Oclaiz alongside Crinetics' Palsonify (paltusotine) as the second new-mechanism acromegaly therapy in the past year, with the Camurus FluidCrystal differentiation focused on a small-volume monthly self-injection.
Camurus' Oclaiz (CAM2029), a once-monthly subcutaneous octreotide depot built on the company's FluidCrystal technology and delivered by autoinjector pen, carries an FDA PDUFA target date of June 10 for acromegaly. The resubmitted NDA, accepted after a Complete Response Letter tied to a third-party manufacturing inspection, rests on seven clinical studies including the two Phase 3 ACROINNOVA trials. A clearance would add a peptide depot to the somatostatin-analog market alongside Crinetics' newly launched oral Palsonify.
Crinetics also disclosed in the May 7 Q1 update that the company is on track to initiate a seamless Phase 2/3 trial of atumelnant in ACTH-dependent Cushing's syndrome in Q2 2026. The trial will assess efficacy in a broad population including Cushing's disease and ectopic ACTH syndrome. Atumelnant is also in Phase 3 for congenital adrenal hyperplasia. Separately, Crinetics announced an exclusive license agreement with Ohio University to develop an early-preclinical growth hormone receptor antagonist (GHRA) for acromegaly — a mechanism complementary to paltusotine's SST2 agonism that would compete in the same indication once both reach market.
Crinetics Pharmaceuticals reported Q1 2026 results May 7 — total revenue $10.7M (vs $8.5M consensus, +25.7% beat), Palsonify (paltusotine) net product revenue $10.3M in its first full commercial quarter (up from $5.4M in Q4 2025), 263 unique prescribers (up from 125 at year-end), 232 new patient enrollment forms in the quarter, and approximately 70% of patients reimbursed with payer coverage above 60% (target above 75% by Q3). Cash, equivalents, and investments closed at $1.3B. R&D rose 17.6% to $100.1M to fund Phase 3 paltusotine in carcinoid syndrome plus atumelnant Phase 3 programs in congenital adrenal hyperplasia and Cushing's syndrome. Shares rose 4.3% in after-hours trading.
Camurus's Oclaiz (CAM2029) — a once-monthly subcutaneous octreotide FluidCrystal depot delivered via prefilled autoinjector — has an FDA Prescription Drug User Fee Act target action date of June 10, 2026, following an October 2024 Complete Response Letter tied to a third-party manufacturer's cGMP inspection. CAM2029's ACROINNOVA Phase 3 program documented approximately five-fold higher bioavailability versus the currently approved long-acting intramuscular octreotide formulation. The June PDUFA sets up a back-to-back acromegaly decision pair with Crinetics' Palsonify (paltusotine), already approved in the EU on April 27 and reported $10.3M in Q1 US net product revenue (covered above). Both target the same patient population through different routes — once-daily oral nonpeptide vs once-monthly subcutaneous peptide depot.
Crinetics Pharmaceuticals announced April 27 that the European Commission approved Palsonify (paltusotine), a selectively-targeted somatostatin receptor type 2 nonpeptide agonist, as the first once-daily oral therapy for acromegaly in adults across all 27 EU member states plus three EEA countries. The approval rests on two pivotal Phase 3 trials in medical-naïve and previously treated patients, with diarrhea, abdominal pain, and nausea reported as the most common adverse reactions and no serious adverse events in the randomized portion. First launches are planned for Germany and Austria, marking Crinetics' first regulatory approval outside the U.S. and a competitive challenge to injectable somatostatin analogs.